Key opinion leaders provide their final thoughts on treatment management for patients with MDS. Ryan Haumschild, PharmD, MS, MBA: Thank you for this rich and informative discussion. Before we conclude ...

Key considerations for appropriate MDS treatment selection are discussed by expert panelists. Ryan Haumschild, PharmD, MS, MBA: Dr Weaver, I’m curious about your thoughts. I’m hearing that there are ...

Myelodysplastic syndromes (MDS) are a group of blood cancers that affect the bone marrow and can result in a low levels of blood cells. When MDS affects red blood cells, it can lead to anemia in some ...

Deep in the bone marrow lies the reason for blood disorders classified as myelodysplastic syndromes—stem cells gone awry. In the mid-1970s, a group of pathologists and clinicians from around the ...

Please provide your email address to receive an email when new articles are posted on . Nearly one-third of patients received a reclassified diagnosis. Seven percent of misdiagnosed patients received ...

The Minimum Data Set (MDS) has been a driving force in many areas of the long-term care sector of healthcare for nearly 30 years. Beginning as an assessment tool to drive the care plan process, and ...